Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9359140 | 0.84 | ALOX15 (0.50) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL17861019 | 0.82 | ALOX15 (0.57) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL3696800 | 0.79 | ALOX15 (0.58) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL8397532 | 0.79 | ALOX15 (0.67) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL8059226 | 0.79 | ALOX15 (0.67) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL6720281 | 0.78 | — | — | |
| SCHEMBL12286363 | 0.77 | ALOX15 (0.75) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL27200268 | 0.77 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL17955374 | 0.77 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL14581768 | 0.77 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | ALOX15 2002/4885ALDH1A1 309/4885NFE2L2 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.